Shenzhen Salubris Pharmaceuticals (002294) Q1 2026 earnings summary

Executive summary

• Achieved revenue of ¥1,228 million, up 15.65% year-over-year, with net profit attributable to shareholders rising 12.45% to ¥225 million.

• Growth driven by higher share of patented and new products, improving gross margin and profitability.

• R&D for international innovative biologics progressing, with key clinical milestones reached for JK07 and JK06.

Financial highlights

• Operating cash flow increased 9.38% year-over-year to ¥185 million.

• Basic and diluted EPS both rose 11.11% to ¥0.20.

• Total assets at quarter-end reached ¥11.41 billion, up 0.95% from year-end; shareholders’ equity up 2.41%.

• Non-recurring profit items totaled ¥3.78 million, mainly from government subsidies and investment income.

Outlook and guidance

• Company continues to advance global strategy, including application for H-share listing in Hong Kong to support international expansion.